RenovoRx, Inc. · NASDAQ:RNXT
RenovoRx — Technical Presentation (June 2020)
15 slides from RenovoRx's technical presentation, June 2020
Slide 1: Trans-Arterial Chemotherapy for Treatment of Locally Advanced Pancreatic Cancer
RENOVO RX Delivering therapy where it matters Trans-Arterial Chemotherapy for Treatment of Locally Advanced Pancreatic Cancer: Treatment Factors Impacting Survival H. Charles Li – RenovoRx Alex S. Tsobanoudis, Jiali Li, Alexander Rosemurgy, J. Augusto Bastidas, Emmanuel Zervos, Steven Goldin, Peter
Slide 2: Disclosures
RENOVO RX Delivering therapy where it matters Disclosures • This study was funded by RenovoRx (Los Altos, CA) 2
Slide 3: LAPC Background and Current Treatments
RENOVO RX Delivering therapy where it matters LAPC Background and Current Treatments • By the end of 2020, pancreatic cancer is expected to be 2nd most deadly cancer • While surgical resection is the best course, due to location of pancreas, tumors in the pancreas are hard to detect until locally ad
Slide 4: LAPC Background and Current Treatments
RENOVO RX Delivering therapy where it matters LAPC Background and Current Treatments • Trans-Arterial Micro Perfusion (TAMP) is a new technique being used to deliver gemcitabine locally to pancreatic adenocarcinoma in patients that are not candidates for curative resection • The technique involves o
Slide 5: RenovoRx is developing therapies for localized treatment of solid cancer tumors
RENOVO RX Delivering therapy where it matters Confidential Do Not Distribute RenovoRx is developing therapies for localized treatment of solid cancer tumors to Increase Survival & Improve Quality of Life RX The RenovoCathTM System Trans-Arterial Micro-Perfusion (TAMP) isolates the anatomy and micro-
Slide 6: Mechanism: pressure mediated Trans-Arterial Micro-Perfusion (TAMP)
RENOVO RX Delivering therapy where it matters Confidential Do Not Distribute Mechanism: pressure Gemcitabine mediated Trans-Arterial distribution Micro-Perfusion (TAMP) At ~45mmHg - tissue pressure is 70 overcome, forcing Distal 60 chemotherapy out 1% balloon of vessel Remaining in Pressure (mmHG) a
Slide 7: Methods
RENOVO RX Delivering therapy where it matters Methods • Eight US sites enrolled 43 patients receiving over 190 total IA treatments using RenovoCath, as part of a Phase I/II safety and follow-up registry studies. Nineteen patients were treatment naïve, 11 patients had prior chemotherapy, and 12 had p
Slide 8: Methods
RENOVO RX Delivering therapy where it matters Methods • We analyzed these data in 43 patients in 2 studies that received up to 190 TAMP treatments • The following variables showed correlation for improved survival in multivariate analysis: • Prior treatment (radiation, chemotherapy, or treatment naï
Slide 9: Results – Prior Treatment
RENOVO RX Delivering therapy where it matters Results – Prior Treatment Prior Treatment on Median OS 30 25 20 p < 0.01 Months 15 10 5 0 Radiation (n=12) Chemo Only (n=11) Tx Naïve (n=19) 9
Slide 10: Results – Treatment Location
RENOVO RX Delivering therapy where it matters Results – Treatment Location Treatment Location on Median OS 35 30 25 20 p < 0.01 Months 15 10 5 0 SMA (n=13) Non-SMA (n=17) Mixed (SMA+Others) (n=13) 10
Slide 11: Results – Number of Treatments
RENOVO RX Delivering therapy where it matters Results – Number of Treatments Number of Treatments on Survival (from 1st Tx) 12 10 8 p < 0.05 Months 6 4 2 0 1-5 Tx (n=27) 6 or more Tx (n=16) 11
Slide 12: Summary/Conclusion
RENOVO RX Delivering therapy where it matters Summary/Conclusion • Intra-arterial gemcitabine/TAMP is safe and efficacious • Increased number of treatment shows greater survival benefits • Patients had varying number of treatments, ranging from 1 to 14 • Patients receiving radiotherapy prior to dire
Slide 13: Mechanism: TAMP combined with radiation
RENOVO RX Delivering therapy where it matters Confidential Do Not Distribute Mechanism : Trans-Arterial Radiation reduces venous Micro-Perfusion (TAMP) outflow by decreasing the combined with radiation microvasculature Distal RenovoCath™ Native vasculature and IA chemo Irradiated vasculature balloon
Slide 14: Summary/Conclusion
RENOVO RX Delivering therapy where it matters Summary/Conclusion • Using the RenovoCath via the SMA showed increased benefit compared to treatment in other arteries. • Despite avascular tumor, the SMA is the largest and closest artery supplying the pancreas. SMA is surrounded by pancreatic tissue =
Slide 15: Summary/Conclusion
RENOVO RX Delivering therapy where it matters Summary/Conclusion • Current Phase III trial on-going to compare intra-arterial gemcitabine (TAMP) vs. SOC gemcitabine and nab-paclitaxel (systemic IV) 15